
BIOLASE BIOL
Quarterly report 2024-Q3
added 11-07-2024
BIOLASE Total Assets 2011-2026 | BIOL
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets BIOLASE
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.1 M | 38.2 M | 55.3 M | 41 M | 31.8 M | 38.5 M | 43 M | 41.9 M | 42.3 M | 59.4 M | 31 M | 32 M | 29.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.4 M | 29.8 M | 40 M |
Quarterly Total Assets BIOLASE
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.2 M | 30.6 M | 34.4 M | 35.1 M | 38.7 M | 39.6 M | 41.9 M | 38.2 M | 42.9 M | 50.9 M | 50.2 M | 55.3 M | 58.5 M | 61.2 M | 63.5 M | 41 M | 41 M | 41 M | 41 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 43 M | 43 M | 43 M | 43 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 42.3 M | 42.3 M | 42.3 M | 42.3 M | 59.4 M | 59.4 M | 59.4 M | 59.4 M | 31 M | 31 M | 31 M | 31 M | 32 M | 32 M | 32 M | 32 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 63.5 M | 27.2 M | 40.6 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
6.21 B | $ 186.6 | 3.28 % | $ 14 B | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
AxoGen
AXGN
|
222 M | $ 34.49 | 3.05 % | $ 1.59 B | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.72 | 3.25 % | $ 1.72 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
9.36 B | $ 292.85 | 1.62 % | $ 8.26 B | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.58 | -0.87 % | $ 36.1 M | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.19 | -4.21 % | $ 119 M | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 40.45 | 3.57 % | $ 6.03 K | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 64.29 | 1.76 % | $ 95.2 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 10.37 | 3.6 % | $ 294 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
53.8 M | $ 25.33 | 1.52 % | $ 214 M | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.03 | 0.01 % | $ 17.4 M | ||
|
Myomo
MYO
|
38.6 M | $ 0.76 | 3.85 % | $ 31.8 M | ||
|
Inogen
INGN
|
299 M | $ 6.45 | - | $ 172 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
5.3 B | $ 95.85 | 3.09 % | $ 13 B | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 1.99 | -1.97 % | $ 1.21 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 4.43 | 3.62 % | $ 938 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
LENSAR
LNSR
|
71.4 M | $ 6.11 | 3.21 % | $ 73.1 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 17.8 | 5.01 % | $ 418 M | ||
|
Delcath Systems
DCTH
|
124 M | $ 10.78 | 3.16 % | $ 386 M | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 56.23 | 2.46 % | $ 1.65 B | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 39.57 | 2.89 % | $ 1.23 B | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 65.44 | 1.33 % | $ 3.57 B | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 89.11 | 1.57 % | $ 3.1 B | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.7 | -0.05 % | $ 123 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 78.24 | 0.15 % | $ 45.8 B |